Aptamers are oligonucleotide sequences with a length of about 25–80 bases which have
abilities to bind to specific target molecules that rival those of monoclonal antibodies. They …

Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research
due to its high efficacy despite dose-limiting toxicities. Several strategies have been …

Soon after they were first described in 1990, aptamers were largely recognized as a new
class of biological ligands that can rival antibodies in various analytical, diagnostic, and …

Precision medicine holds great promise to harness genetic and epigenetic cues for targeted
treatment of a variety of diseases, ranging from many types of cancers, neurodegenerative …

Surface functionalization of liposomes can play a key role in overcoming the current
limitations of nanocarriers to treat solid tumors, ie, biological barriers and physiological …

Aptamers are single-stranded DNA or RNA molecules capable of tightly binding to specific
targets. These functional nucleic acids are obtained by an in vitro Darwinian evolution …

Aptamers are short DNA/RNA oligonucleotides capable of binding to target molecules with
high affinity and specificity. The process of selecting an aptamer is called Systematic …

Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer
therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using …

The continuing increase of cancer morbidity and death rate requires efficient therapeutic
strategies. The traditional chemotherapy usually fails to treat cancer or prolong survival rate …

Liposomes are spherical-enclosed membrane vesicles mainly constructed with lipids. Lipid
nanoparticles are loaded with therapeutics and may not contain an enclosed bilayer. The …